Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-18T23:14:20.607Z Has data issue: false hasContentIssue false

Reasons to choose a long acting antipsychotic and tolerability

Published online by Cambridge University Press:  23 March 2020

N. Gómez-Coronado Suárez de Venegas
Affiliation:
Hospital Universitario Virgen del Rocío, Salud Mental, Seville, Spain
P. Blanco Ramón
Affiliation:
Hospital Universitario Virgen del Rocío, Salud Mental, Seville, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Aripiprazole depot is an atypical antipshycotic used to treat positive and negative symptoms of psychosis or acute mania.

Aim

Describe the reason why psychiatrists switch the current antipsychotic treatment on to aripiprazol depot, its tolerability and the reasons to stop aripiprazol depot treatment.

Methods

Descriptive analysis based on a sample of 37 patients, aged 18–65 years, treated during one year with antipsychotics at two community mental health units.

Results

Switching on to aripiprazole depot principal reasons: promote adherence (25%), persistence of symptoms (25%) and high levels of prolactin or sexual dysfunction (16.66%):

– side effects of aripiprazole depot: insomnia (11.11%), inquietude (8.33%), sexual dysfunction (2.77%) and hypertensive crisis during administration (2.77%);

– 83.33% of the patients are still taking it after one year. The most common reasons to stop or change it were the presence of secondaries (11.11%) and clinical exacerbation (5.55%).

Conclusions

Aripiprazole depot is well tolerated (even better than other antipsychotics). Common side effects are not severe and appear in a small percent of patients.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster Viewing: Schizophrenia and other psychotic disorders
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.